Let us wake the nation on the treatment for age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 21, Issue 3, 2010, Pages 169-171

  Brown, Gary ^a,b,c   Brown, Melissa M ^c,d  

^a Wills Eye Institute   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c CENTER FOR VALUE BASED MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Age related macular degeneration; Public perceptions; Quality of life

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN A;

CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FUNCTIONAL STATUS; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; URETER STONE; VISION;

HEALTH EDUCATION; HUMANS; MACULAR DEGENERATION; PUBLIC OPINION; QUALITY OF LIFE; UNITED STATES;

EID: 77951278567     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283388605     Document Type: Review

References (15)

1. Brown GC, Brown MM. Comparative effectiveness. Curr Opin Ophthalmol 2009; 20:147-150.
2. Brown GC, Brown MM, Sharma S. Difference between ophthalmologist and patient perceptions of quality-of-life associated with age-related macular degeneration. Can J Ophthalmol 2000; 35:27-32.
3. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc 1999; 97:473-512.
4. Brown MM, Brown GC, Sharma S. Evidence-based to value-based medicine. Chicago: AMA Press; 2005:; pp. 1-324.
5. Brown MM, Brown GC, Stein JD, et al. Age-related macular degeneration: economic burden and value-based analysis. Can Ophthalmol 2005; 40:277-287.
6. Stein JD, Brown MM, Brown GC, et al. Quality of life with macular degeneration: perceptions of patients, clinicians and community members. Br J Ophthalmol 2003; 87:8-12.
7. Duncan PW, Lai SM, Keighley J. Defining poststroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 2000; 39:835-841.
8. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2009; 38:583-637.
9. Real FJ, Brown GC, Brown H, Brown MM. The effect of comorbidities upon patient health-related quality of life. Br J Ophthalmol 2008; 92:770-774.
10. Rosenfeld PJ, Brown DM, Heier JS, et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006; 355:1419-1431.
11. BrownGC, Brown MM, Brown H, Peet JS. A value-based medicine analysis of ranibizumab (MARINA Study) for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115:1039-1045.
12. Brown MM, Brown GC, Brown HC, et al. Comparative effectiveness and costeffectiveness analyses of VEGF-A inhibitor and 90Sr brachytherapy for neovascular macular degeneration. Evid-Based Ophthalmol 2009; 10:107-122.
13. Brown GC, Brown MM, Gupta O, Shah C. The socio-economic contribution of therapy for neovascular AMD. Presented at the American Academy of Ophthalmology 2009 Subspecialty Day, Retina 2009: The Cutting Edge, October 24, 2009.
14. Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol 2004; 15:181-183.
15. Ion L, Goldfracht M, Bech P. 'Do you think you suffer from depression?' Reevaluating the use of a single item question for the screening of depression in older primary care patients. Int J Geriatr Psychiatry 2009. [Epub ahead of print]